

- **Name:** Hye Ryun Kim
- **Current Position & Affiliation:** Professor, Medical Oncology, Yonsei Cancer Center
- **Country:** KOREA

---

• **Educational Background:**

She graduated from Yonsei University College of Medicine and trained for Residency and Clinical Fellowship in Internal Medicine and Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine.

• **Professional Experience:**

Dr. Hye Ryun Kim is a Professor of Medical Oncology and the Chief of the Lung Cancer Center at Yonsei Cancer Center. She is a leading expert in the development of novel therapeutic strategies for lung and head and neck cancers, with a strong focus on clinical trials. Dr. Kim has authored over 100 peer-reviewed publications, including several as first or corresponding author in high-impact journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, and Nature Communications. Her research interests center on elucidating resistance mechanisms to targeted therapies and defining the determinants of the tumor-immune microenvironment in lung cancer. She leads multiple clinical trials, including investigator-initiated studies exploring innovative treatment approaches. Dr. Kim's work is supported by national research grants, including funding from the National Research Foundation for projects on single-cell multiomics analysis of the tumor microenvironment.

• **Professional Organizations:**

Chief of the Lung Cancer Center in Yonsei Cancer Center  
 Director, Center for Human Resources Development in Yonsei University Health System  
 Vice Secretary General, Korean Association for Lung Cancer  
 Director of Treasurer, The Korean Society for Head & Neck Oncology)  
 Scientific Committee member, WCLC  
 Scientific Committee member, ELCC

• **Main Scientific Publications:**

Hong MH, Choi YJ, Ahn HK, Lim SM, Keam B, Kim DW, Kim TM, Youk J, Kim YJ, Hwang S, Kim S, Kim JW, **Kim HR**, Kang JH. Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial. *JAMA Oncol.* 2024 Oct 1;10(10):1342-1351 (Correspondence)

Cho JW, Park S, Kim G, Han H, Shim HS, Shin S, Bae YS, Park SY, Ha SJ, Lee I, **Kim HR**. Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with

unfavorable anti-PD-1 responses in EGFR-mutant lung cancer. *Nat Commun.* 2021 Oct (Correspondence)

BS Keam, MH Hong, SH Shin, SG Heo, JE Kim, HK Ahn, YG Lee, KU Park, Tak Yun, KW Lee, SB Kim, SC Lee, MK Kim, SH Cho, SY Oh, SG Park, SW Hwan, BH Nam, SW Kim, **HR Kim**, Hwan JY. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial *Journal of Clinical Oncology* 2023 (Correspondence)

Kim CG, Hong MH, Kim D, Lee BH, Kim H, Ock CY, Kelly G, Bang YJ, Kim G, Lee JE, Kim C, Kim SH, Hong HJ, Park YM, Sim NS, Park H, Park JW, Lee CG, Kim KH, Park G, Jung I, Han D, Kim JH, Cha J, Lee I, Kang M, Song H, Oum C, Kim S, Kim S, Lim Y, Kim-Schulze S, Merad M, Yoon SO, Kim HJ, Koh YW, **Kim HR**. A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res.* 2024 May 15;30(10):2097-2110 (Correspondence)

Kim CG, Kim G, Kim KH, Park S, Shin S, Yeo D, Shim HS, Yoon HI, Park SY, Ha SJ, **Kim HR**. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. *J Immunother Cancer.* 2021 Dec (Correspondence)

Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csősz, Parneet K. Cheema, Delvys Rodriguez-Abreu, Mirjana Wollner, James Chih-Hsin Yang, Julien Mazieres, Francisco J. Orlandi, Alexander Luft, Mahmut Gümüş, Terufumi Kato, Gregory P. Kalemkerian, Yiwen Luo, Victoria Ebiana, M. Catherine Pietanza, and **Hye Ryun Kim** Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. *Journal of Clinical Oncology* (senior author)